Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.
礼来礼来(US:LLY) WSJ·2026-05-07 17:30

文章核心观点 - 投资者过度关注GLP-1类药物在美国市场的使用情况，但国际市场的销售表现同样至关重要 [1] 市场关注点分析 - 当前投资者的焦点集中在GLP-1口服药在美国市场的接受度上 [1] - 文章指出，这种关注存在片面性，忽略了国际市场的重要性 [1] 市场机会评估 - GLP-1类药物的国际市场销售是评估该行业公司增长潜力的关键因素，其重要性不亚于美国本土市场 [1]

Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S. - Reportify